No Data
Cantor Fitzgerald Reiterates Overweight on Kura Oncology
LifeSci Capital Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $30
Buy Rating for Kura Oncology Supported by Promising Ziftomenib Data and Strategic Drug Development
Kura Oncology to Present Updated Data From KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
Earnings Preview: KURA to Report Financial Results Post-market on November 07
$Kura Oncology(KURA.US)$ is scheduled to release its financial results post-market on November 07 ET. Earnings PreviewAnalysts estimate $Kura Oncology(KURA.US)$ to post revenue of USD0 for 2024Q3,
Kura Oncology (NASDAQ:KURA) Has Debt But No Earnings; Should You Worry?